Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alisol B is a tetracyclic triterpenoid compound isolated primarily from the rhizome of Alisma orientale, a plant used in traditional Chinese medicine. It is a small molecule inhibitor that targets the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase pump (SERCA), thereby disrupting calcium homeostasis in cells. This disruption leads to calcium mobilization from internal stores, resulting in endoplasmic reticulum stress, autophagy induction (via the CaMKK-AMPK-mTOR pathway), cell cycle arrest in G1 phase, and apoptosis in various cancer cell lines. Alisol B is hence studied as a potential antitumor agent and a research compound for modulating calcium signaling, cell death, and autophagy[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alisol B.